RT Journal Article
T1 Feasibility of treatment discontinuation in chronic myeloid leukemia in clinical practice: results from a nationwide series of 236 patients.
A1 Hernández-Boluda, Juan Carlos
A1 Pereira, Arturo
A1 Pastor-Galán, Irene
A1 Alvarez-Larrán, Alberto
A1 Savchuk, Alisa
A1 Puerta, José Manuel
A1 Sánchez-Pina, José María
A1 Collado, Rosa
A1 Díaz-González, Alvaro
A1 Angona, Anna
A1 Sagüés, Miguel
A1 García-Gutiérrez, Valentín
A1 Boqué, Concepción
A1 Osorio, Santiago
A1 Vallansot, Rolando
A1 Palomera, Luis
A1 Mendizábal, Arantxa
A1 Casado, Luis Felipe
A1 Pérez-Encinas, Manuel
A1 Pérez-López, Raúl
A1 Ferrer-Marín, Francisca
A1 Sánchez-Guijo, Fermín
A1 García, Carmen
A1 Heras, Natalia de Las
A1 López-Lorenzo, José Luis
A1 Cervantes, Francisco
A1 Steegmann, Juan Luis
A1 Grupo Español de Leucemia Mieloide Crónica (GELMC), 
AB Over half of chronic myeloid leukemia (CML) patients in deep molecular response do not lose the major molecular response (MMR) after stopping treatment with tyrosine kinase inhibitors (TKI). This strategy is safe in clinical trials, but its applicability in the real-life setting remains unsettled. We describe the outcomes after TKI discontinuation in a nationwide series of 236 CML patients. Median follow-up from treatment discontinuation was 21.5 months and 5 patients died from CML-unrelated causes. TKI therapy was reinitiated due to MMR loss (n = 52), increase ≥ 1 log in BCR-ABL transcript level without losing MMR (n = 12), patient preference (n = 2), and withdrawal syndrome (n = 1). Treatment-free remission rate at 4 years was 64% (95% confidence interval, CI: 55%-72%). Cumulative incidence of molecular recurrence at 3 years was 33% (95% CI: 26%-38%). TKI treatment for
YR 2018
FD 2018-12-02
LK http://hdl.handle.net/10668/13270
UL http://hdl.handle.net/10668/13270
LA en
DS RISalud
RD Apr 18, 2025